"Growth hormone" quickly "out of the circle", Anke Bio-Human Growth Hormone Injection was approved to increase 2 indications

 Growth hormone is a common main treatment method for short stature diseases.
In recent years, growth hormone treatment methods have suddenly entered the field of vision of more and more parents, and the concept of "growth hormone" has quickly "out of the circle" in the capital market
.
On December 30, Anke Biological issued a noon announcement that the company's human growth hormone injection drug supplement application was approved
.
According to the announcement, Anke Biotechnology recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration.
The company's human growth hormone injection is used for the growth disorder, A supplementary application for the indications for idiopathic short stature has been approved
.
It is understood that Anke Bio's human growth hormone for injection was approved in July 2021 and September 2021, respectively, for the newly added Turner syndrome indications and idiopathic short stature (English abbreviation: ISS) indications, which will be injected in the company On the basis of the approval of the indications for human growth hormone, the supplementary application for human growth hormone injection is to add the above two indications
.
So far, Anke Bio's human growth hormone injection has been approved for marketing in 8 indications, which are as follows: ①For children who are slow to grow due to endogenous growth hormone deficiency; ②For those caused by Noonan syndrome Children with short stature; ③for children with short stature or growth disorders caused by SHOX gene defects; ④for severe burn treatment; ⑤for children with short stature caused by achondroplasia; ⑥for adults receiving nutritional support Short bowel syndrome; ⑦for growth disorders in girls caused by gonadal hypoplasia (Turner syndrome);⑧for idiopathic short stature
.
It is reported that on December 30, Anke Biotech rose rapidly in the intraday market, with an increase of more than 2% within 5 minutes.
As of 13:00, it was reported at 13.
08 yuan, with a turnover of 166 million yuan and a turnover rate of 1.
12%
.
Some analysts said that the growth hormone treatment method has attracted more and more attention from parents, and the growth hormone market may usher in a broad space for development in the future.

.
The author was informed that, in addition to the above-mentioned breakthroughs in the human growth hormone injection field by Anke Biotech, Jichuan Pharmaceuticals recently issued an announcement stating that the company is expected to spend more than 2 billion yuan to obtain Tianjing Biotech through the License-in (licensed introduction) model.
License for the development, production and commercialization of Yitan long-acting recombinant human growth hormone (TJ101) in the Chinese market
.
It is reported that three days after the announcement of Jichuan Pharmaceutical, the company's share price rose by 33.
18%, and its market value rose by nearly 5 billion yuan
.
Jichuan Pharmaceutical said that from the perspective of market capacity, third-party research data shows that currently only 5.
7% of children with growth hormone deficiency in China are expected to receive growth hormone injections, and clinical needs have largely not been met
.
“By 2030, China’s growth hormone deficiency market is expected to exceed RMB 30 billion.
Such a large market can fully accommodate the joint development of several manufacturers and jointly promote the development of the industry
.
” Jichuan Pharmaceutical went on to say, “From According to the channels that Jichuan has deployed, there are currently more than 1,700 public hospitals above the third level, more than 3,700 second-level hospitals, and more than 18,000 first-level and community hospitals
.
Among these hospitals, there are more than 220 specialized hospitals for children.
There are about 230 special children's hospitals nationwide, and we have basically achieved full coverage
.
In addition, we currently cover more than 60,000 clinics
.
These are powerful guarantees for the rapid commercialization of the subsequent TJ101 after the launch
.
" But Some insiders also pointed out that as an endocrine treatment method, the use of growth hormone is complicated
.
The clinical application of growth hormone has only been six to seventy years, and the medical community still lacks an understanding of its nature
.
For any patient, the proper use of growth hormone requires the strict control of professional doctors
.